Show simple item record

dc.contributor.authorFröbert, Ole
dc.contributor.authorLagerqvist, Bo
dc.contributor.authorGudnason, Thorarinn
dc.contributor.authorThuesen, Leif
dc.contributor.authorSvensson, Roger
dc.contributor.authorOlivecrona, Göran K
dc.contributor.authorJames, Stefan K
dc.date.accessioned2011-01-06T10:02:58Z
dc.date.available2011-01-06T10:02:58Z
dc.date.issued2010-12
dc.date.submitted2011-01-06
dc.identifier.citationAm. Heart J. 2010, 160(6):1042-8en
dc.identifier.issn1097-6744
dc.identifier.pmid21146656
dc.identifier.doi10.1016/j.ahj.2010.08.040
dc.identifier.urihttp://hdl.handle.net/2336/118805
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links fielden
dc.description.abstractBACKGROUND: In ST-elevation myocardial infarction (STEMI), distal embolization of thrombus material often precludes restoration of normal coronary artery flow. Small-scaled studies have demonstrated that intracoronary thrombus aspiration improves flow and myocardial perfusion, but only one larger randomized single-center study has suggested a survival benefit. Thrombus aspiration is widely used in clinical practice and is recommended by international guidelines despite limited evidence. METHODS/DESIGN: The Thrombus Aspiration in ST-Elevation myocardial infarction in Scandinavia is a multicenter, prospective, randomized, controlled, clinical open-label trial based on the Swedish angiography and angioplasty registry (SCAAR) platform with blinded evaluation of end points. A total of 5,000 patients with STEMI undergoing primary percutaneous coronary intervention (PCI) will randomly be assigned either to conventional PCI or to thrombus aspiration followed by PCI. SCAAR will be used as the platform for randomization, allowing a broad population of all-comers in the registry network to be enrolled. All follow-up will also be done in SCAAR and other national registries. The primary end point is time to all-cause death at 30 days. DISCUSSION: The Thrombus Aspiration in ST-Elevation myocardial infarction in Scandinavia trial is the largest trial to date to evaluate the effect of thrombus aspiration on death following PCI in patients with STEMI. We propose the term randomized clinical registry trial to describe the novel entity of using an online national registry as platform for case records, randomization, and follow-up.
dc.language.isoenen
dc.publisherMosbyen
dc.relation.urlhttp://dx.doi.org/10.1016/j.ahj.2010.08.040en
dc.subject.meshMyocardial Infarctionen
dc.subject.meshResearch Designen
dc.subject.meshCoronary Thrombosisen
dc.subject.meshPubmed in processen
dc.titleThrombus Aspiration in ST-Elevation myocardial infarction in Scandinavia (TASTE trial). A multicenter, prospective, randomized, controlled clinical registry trial based on the Swedish angiography and angioplasty registry (SCAAR) platform. Study design and rationaleen
dc.typeArticleen
dc.contributor.departmentDepartment of Cardiology, Örebro University Hospital, Örebro, Sweden. ole.frobert@orebroll.seen
dc.identifier.journalAmerican heart journalen
html.description.abstractBACKGROUND: In ST-elevation myocardial infarction (STEMI), distal embolization of thrombus material often precludes restoration of normal coronary artery flow. Small-scaled studies have demonstrated that intracoronary thrombus aspiration improves flow and myocardial perfusion, but only one larger randomized single-center study has suggested a survival benefit. Thrombus aspiration is widely used in clinical practice and is recommended by international guidelines despite limited evidence. METHODS/DESIGN: The Thrombus Aspiration in ST-Elevation myocardial infarction in Scandinavia is a multicenter, prospective, randomized, controlled, clinical open-label trial based on the Swedish angiography and angioplasty registry (SCAAR) platform with blinded evaluation of end points. A total of 5,000 patients with STEMI undergoing primary percutaneous coronary intervention (PCI) will randomly be assigned either to conventional PCI or to thrombus aspiration followed by PCI. SCAAR will be used as the platform for randomization, allowing a broad population of all-comers in the registry network to be enrolled. All follow-up will also be done in SCAAR and other national registries. The primary end point is time to all-cause death at 30 days. DISCUSSION: The Thrombus Aspiration in ST-Elevation myocardial infarction in Scandinavia trial is the largest trial to date to evaluate the effect of thrombus aspiration on death following PCI in patients with STEMI. We propose the term randomized clinical registry trial to describe the novel entity of using an online national registry as platform for case records, randomization, and follow-up.


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record